Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate

Journal of Bone and Mineral Research

Volumn 22, Issue 1, 2007, Pages 142-148

  Hosking, David ^a   Lyles, Kenneth ^b   Brown, Jacques P ^c   Fraser, William D ^d   Miller, Paul ^e   Diaz Curiel, Manuel ^f   Devogelaer, Jean Pierre ^g   Hooper, Michael ^h   Su, Guoqin ⁱ   Zelenakas, Ken ⁱ   Pak, Judy ⁱ   Fashola, Taiwo ⁱ   Saidi, Youssef ⁱ   Eriksen, Erik Fink ⁱ   Reid, Ian R ^j  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c LAVAL UNIVERSITY   (Canada)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^e University of Colorado Health Sciences Center   (United States)

^f UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^g UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY OF AUCKLAND   (New Zealand)

more..

Author keywords

Bone turnover; Paget's disease; Remission; Risedronate; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE MALFORMATION; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; FEMALE; FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OSTEOARTHRITIS; PAGET BONE DISEASE; REMISSION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; OSTEITIS DEFORMANS;

EID: 33845933979     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.061001     Document Type: Article

References (27)

1. Lyles KW, Siris ES, Singer FR, Meunier PJ 2001 A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res 16:1379-1387.
2. Selby PL, Davie MWJ, Ralston SH, Stone MD 2002 Guidelines on the management of Paget's disease of bone. Bone 31:366-373.
3. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen containing bisphosphonates. J Pharmacol Exp Ther 296:235-242.
4. Green JR, Rogers MJ 2002 Pharmacologie profile of zoledronic acid: A highly potent inhibitor of bone resorption. Drug Dev Res 55:210-224.
5. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Guide S, Wu W, Mangood A, Russell RG, Ebetino FH 2006 Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38:617-627.
6. Reid IR, Miller P, Lyles K, Fraser W, Brown J, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D 2005 A single infusion of zoledronic acid improves remission rates in Paget's disease: A randomized controlled comparison with risedronate. N Engl J Med 353:898-908.
7. Van Staa TP, Selby P, Leufkens HGM, Lyles K, Sprafka JM, Cooper C 2002 Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 17:465-471.
8. Gray RE, Yates AJ, Preston CJ, Smith R, Russell RG, Kanis JA 1987 Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Q J Med 64:755-767.
9. Patel S, Stone MD, Coupland C, Hosking DJ 1993 Determinants of remission of Paget's disease of bone. J Bone Miner Res 8:1467-1473.
10. Garnero P, Ginetys E, Schaffer AV, Seaman J, Delmas PD 1998 Measurement of urinary excretion of nonisomerized and beta isomerized forms of type 1 collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum 41:354-360.
11. Harinck HI, Papapoulos SE, Blanksma HJ, Moolenar AJ, Vermeij P, Bijvoet OL 1987 Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). BMJ 295:1301-1305.
12. Schweitzer DH, Zwinderman AH, Vermeij P, Bijvoet OL, Papapoulos SE 1993 Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 8:175-182.
13. Khan SA, McCloskey EV, Nakatsuka K, Orgee J, Coombes GM, Kanis JA 1996 Duration of response with oral clodronate in Paget's disease of bone. Bone 18:185-190.
14. Eekhoff MEMW, Zwinderman AH, Haverkort DMAD, Cremers SCLM, Hamdy NAT, Papapoulos SE 2003 Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. Bone 33:831-838.
15. Stone MD, Marshall DH, Hosking DJ, Perkins AC, Evans AJ, Wastie ML 1992 Bisphosphonate space measurement in Paget's disease of bone treated with APD. J Bone Miner Res 7:295-301.
16. Cremers SCLM, Eekhoff MEMW, Den Hartigh J, Hamdy NAT, Vermeij P, Papapoulos SE 2003 Relation between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (Olpadronate) in patients with Paget's disease of bone. J Bone Miner Res 18:868-875.
17. Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ 1998 Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study. J Bone Miner Res 13:1032-1038.
18. Siris ES, Weinstein RS, Altman RD, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M 1996 Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81:961-967.
19. Alvarez L, Peris P, Guanabens N, Vidal S, Quinto LI, Monegal A, Pons F, Ballesta AM, Munoz-Gomez J 2004 Long term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment. Rheumatol 43:869-874.
20. Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, Rutland MD, Cundy T 2004 Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 35:224-230.
21. Blumsohn A, Naylor KE, Assiri AMA, Eastell R 1995 Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease. Clin Chem 41:1592-1598.
22. Alexandersen P, Peris P, Guanabens N, Byrjalsen I, Solberg H, Cloos PAC 2005 Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res 20:588-595.
23. Altman RD, Johnston CC, Khari MRA, Wellman H, Serafini AN, Sankey RR 1973 Influence of disodium etidronate on clinical and laboratory manifestations of Pagets disease of bone (osteitis deformans). N Engl J Med 289:1379-1384.
24. Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BGA, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH 2004 A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone 34:747-754.
25. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL 2004 Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62:527-534.
26. Carter G, Goss AN, Doecke C 2005 Bisphosphonates and avascular necrosis of the jaw: A possible association. Med J Aust 182:413-415.
27. Woo S-B, Hellstein JW, Kalmar JR 2006 Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761.